SEC Form 4
Incyte Genomics Inc (INCY) insider trading
In the 12 months to Oct 26, 2026, 10 INCY insiders reported open-market sales of $58.3M across 29 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $58.3M
- 29 filings · 10 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 29 of 29
- All $58.3M sold was pre-arranged
Who traded INCY, and when
- Sale
- Sale, pre-arranged (10b5-1)
INCY daily close from Oct 27, 2025 to Oct 26, 2026, between $90.18 and $129.93, last $113.54. 29 sale and 0 purchase filings by 10 insiders, marked at their filing dates. Herve Hoppenot, Director: sold $19.8M across 1 filing, first filed Nov 12, 2025, last Nov 12, 2025. Pablo J. Cagnoni, President, R&D → President, Global Head of R&D: sold $14.4M across 9 filings, first filed Feb 23, 2026, last Oct 19, 2026. Steven H. Stein, EVP & Chief Medical Officer → CMO & Head of Late-Stage Dev.: sold $7.9M across 5 filings, first filed Nov 7, 2025, last Jul 20, 2026. Patrick A. Mayes, EVP & Chief Scientific Officer: sold $6.6M across 3 filings, first filed Dec 12, 2025, last Aug 7, 2026. Michael James Morrissey, EVP, Head of Tech. Operations: sold $5.7M across 1 filing, first filed Dec 18, 2025, last Dec 18, 2025. Paul J. Clancy, Director: sold $1.4M across 1 filing, first filed May 21, 2026, last May 21, 2026. 4 others: sold $2.6M across 9 filings, first filed Nov 5, 2025, last Jul 20, 2026.
Largest mark · tap a row for others
Herve Hoppenot · Director
Sale $19,773,750
187,500 shares at $105.46 avg
Filed Nov 12, 2025 · traded Nov 10
Pre-arranged (10b5-1) · close on filing date $108.26
Herve Hoppenot · Director
Director
$19.8M soldPablo J. Cagnoni · President, R&D → President, Global Head of R&D
President, R&D → President, Global Head of R&D
$14.4M soldSteven H. Stein · EVP & Chief Medical Officer → CMO & Head of Late-Stage Dev.
EVP & Chief Medical Officer → CMO & Head of Late-Stage Dev.
$7.9M soldPatrick A. Mayes · EVP & Chief Scientific Officer
EVP & Chief Scientific Officer
$6.6M soldMichael James Morrissey · EVP, Head of Tech. Operations
EVP, Head of Tech. Operations
$5.7M soldPaul J. Clancy · Director
Director
$1.4M sold4 others
Combined, one mark per week
$2.6M soldOpen-market trades
29 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Herve Hoppenot | Director | $19.8M | — | 1 | 100% of sales | |
| Pablo J. Cagnoni | President, R&D → President, Global Head of R&D | $14.4M | — | 9 | 100% of sales | |
| Steven H. Stein | EVP & Chief Medical Officer → CMO & Head of Late-Stage Dev. | $7.9M | — | 5 | 100% of sales | |
| Patrick A. Mayes | EVP & Chief Scientific Officer | $6.6M | — | 3 | 100% of sales | |
| Michael James Morrissey | EVP, Head of Tech. Operations | $5.7M | — | 1 | 100% of sales | |
| Paul J. Clancy | Director | $1.4M | — | 1 | 100% of sales | |
| Mohamed Khairie Issa | EVP, Head of US Oncology → EVP, Head of U.S. Commercial | $1.3M | — | 2 | 100% of sales | |
| Thomas Tray | Principal Accounting Officer | $879.0K | — | 4 | 100% of sales | |
| Lee Heeson | EVP, Head of Incyte Intl | $289.0K | — | 1 | 100% of sales | |
| Sheila A. Denton | EVP & General Counsel | $89.6K | — | 2 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Pablo J. Cagnoni President, Global Head of R&D | SalePre-arranged (10b5-1) | 2,642 | $112.71 | $297.8K | 183,200 | |
traded | Pablo J. Cagnoni President, Global Head of R&D | SalePre-arranged (10b5-1) | 23,218 | $120.49 | $2.8M | 183,200 | |
traded | Pablo J. Cagnoni President, Global Head of R&D | SalePre-arranged (10b5-1) | 10,801 | $125.56 | $1.4M | 183,200 | |
traded | Pablo J. Cagnoni President, Global Head of R&D | SalePre-arranged (10b5-1) | 10,803 | $120.04 | $1.3M | 194,001 | |
traded | Pablo J. Cagnoni President, Global Head of R&D | SalePre-arranged (10b5-1) | 10,640 | $122.69 | $1.3M | 204,804 | |
traded | Patrick A. Mayes EVP & Chief Scientific Officer | SalePre-arranged (10b5-1) | 2,207 | $123.99 | $273.6K | 61,441 | |
traded | Pablo J. Cagnoni President, Global Head of R&D | SalePre-arranged (10b5-1) | 15,888 | $119.70 | $1.9M | 215,444 | |
traded | Patrick A. Mayes EVP & Chief Scientific Officer | SalePre-arranged (10b5-1) | 47,954 | $119.58 | $5.7M | 61,441 | |
traded | Steven H. Stein CMO & Head of Late-Stage Dev. | SalePre-arranged (10b5-1) | 1,877 | $114.73 | $215.3K | 21,118 | |
traded | Mohamed Khairie Issa EVP, Head of U.S. Commercial | SalePre-arranged (10b5-1) | 1,093 | $115.01 | $125.7K | 63,940 | |
traded | Steven H. Stein CMO & Head of Late-Stage Dev. | SalePre-arranged (10b5-1) | 28,237 | $113.05 | $3.2M | 26,083 | |
traded | Thomas Tray Principal Accounting Officer | SalePre-arranged (10b5-1) | 2,639 | $100.00 | $263.9K | 21,132 | |
traded | Thomas Tray Principal Accounting Officer | SalePre-arranged (10b5-1) | 2,051 | $97.35 | $199.7K | 21,132 | |
traded | Paul J. Clancy Director | SalePre-arranged (10b5-1) | 15,000 | $94.93 | $1.4M | 23,741 | |
traded | Pablo J. Cagnoni President, Global Head of R&D | SalePre-arranged (10b5-1) | 18,667 | $96.50 | $1.8M | 262,692 | |
traded | Pablo J. Cagnoni President, R&D | SalePre-arranged (10b5-1) | 18,667 | $94.24 | $1.8M | 234,800 | |
traded | Pablo J. Cagnoni President, R&D | SalePre-arranged (10b5-1) | 18,668 | $100.91 | $1.9M | 234,800 | |
traded | Mohamed Khairie Issa EVP, Head of US Oncology | SalePre-arranged (10b5-1) | 10,856 | $109.07 | $1.2M | 66,132 | |
traded | Steven H. Stein EVP & Chief Medical Officer | SalePre-arranged (10b5-1) | 15,634 | $101.70 | $1.6M | 34,203 | |
traded | Thomas Tray Principal Accounting Officer | SalePre-arranged (10b5-1) | 3,374 | $99.69 | $336.4K | 22,973 | |
traded | Michael James Morrissey EVP, Head of Tech. Operations | SalePre-arranged (10b5-1) | 58,331 | $97.29 | $5.7M | 27,507 | |
traded | Patrick A. Mayes EVP & Chief Scientific Officer | SalePre-arranged (10b5-1) | 5,808 | $95.55 | $555.0K | 60,011 | |
traded | Steven H. Stein EVP & Chief Medical Officer | SalePre-arranged (10b5-1) | 22,664 | $102.56 | $2.3M | 63,129 | |
traded | Thomas Tray Principal Accounting Officer | SalePre-arranged (10b5-1) | 769 | $102.78 | $79.0K | 23,573 | |
traded | Sheila A. Denton EVP & General Counsel | SalePre-arranged (10b5-1) | 278 | $104.36 | $29.0K | 26,569 | |
traded | Herve Hoppenot Director | SalePre-arranged (10b5-1) | 187,500 | $105.46 | $19.8M | 329,646 | |
traded | Steven H. Stein EVP & Chief Medical Officer | SalePre-arranged (10b5-1) | 5,233 | $102.20 | $534.8K | 102,886 | |
traded | Sheila A. Denton EVP & General Counsel | SalePre-arranged (10b5-1) | 598 | $101.36 | $60.6K | 26,569 | |
traded | Lee Heeson EVP, Head of Incyte Intl | SalePre-arranged (10b5-1) | 3,074 | $94.02 | $289.0K | 29,241 |
GET /stocks/filings/vX/form-4?tickers=INCY&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"INCY"
],
"issuer_cik": "0000879169",
"owner_cik": "0001205703",
"accession_number": "0001205703-26-000032",
"form_type": "4",
"filing_date": "2026-10-19",
"period_of_report": "2026-10-15",
"issuer_name": "INCYTE CORP",
"issuer_trading_symbol": "INCY",
"owner_name": "CAGNONI PABLO J",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "President, Global Head of R&D",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-15",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 2642,
"transaction_price_per_share": 112.71,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 183200,
"transaction_value": 297779.82,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested."
}
]
},
{
"tickers": [
"INCY"
],
"issuer_cik": "0000879169",
"owner_cik": "0001205703",
"accession_number": "0001205703-26-000030",
"form_type": "4",
"filing_date": "2026-09-17",
"period_of_report": "2026-09-15",
"issuer_name": "INCYTE CORP",
"issuer_trading_symbol": "INCY",
"owner_name": "CAGNONI PABLO J",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "President, Global Head of R&D",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-15",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 9233,
"transaction_price_per_share": 120.5,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 197185,
"transaction_value": 1112576.5,
"not_subject_to_section_16": false,
"direct_or_indirect": "D"
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 113 records
- Option exercises44 records
- Tax withholding28 records
- Grants and awards41 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Role
- The title on each filing. Someone whose title changed shows more than one.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Incyte Genomics Inc's CEO sold stock?
No. William Meury (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is INCY’s insider data?
These are INCY Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track INCY insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for INCY every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.